Please note that the website is being retired as of May 31, 2019. Please revise your bookmarks to use the Quest Test Directory for your inquiries:

Welcome to the new Quest Diagnostics Test Directory

Search with confidence for the right test! Use our helpful education resources, and tools to narrow your search by specialty and test category, and compare tests side-by-side.
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Infectious Disease
Women's Health
91416: Accutype(r) Ribavirin (itpa) Print View
rs112735 genotype PCR     
rs7270101 genotype PCR     

Management of HCV infected patients requires the ability for clinicians to appropriately handle therapeutic side effects from the standard of care therapy of PegIFN/Ribavirin, the most common and important is RBV (Ribavirin) induced haemolytic anemia. Medical recourse for the onset of RBV induced haemolytic anemia requires dose modification of the PegIFN/Ribavirin combination therapy. A dose reduction of RBV directly affects treatment efficacy. Previous studies demonstrated ITPA variants protect agains anemia. The FDA approval of the direct-acting antiviral (DAA) drugs for treatment of HCV has lead to improve sustained viral response (SVR) for genotype 1 patients by up to 79%. IL28B genotype testing is a pretreatment predictor for HCV patient's response to pegylated interferon (PEGIN/Ribavirin combination therapy) therapy. The IL28B testing does not provide clear medical decision when testing for DAA's in combination with PegIFN/Ribavirin. Two functional variants on inosine triphosphate pyrophosphatase (ITPA) [rs1127354 and rs7270101] have shown strong association for ITPase deficiency, which is a clear factor for early-onset anemia in patient's Ribavirin therapy.

Whole blood: Normal phlebotomy procedure. Store and ship room
temperature immediately. Do not freeze.
Setup Schedule

Reported (Analytical Time)
3 days

CPT Code

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Rejection Criteria: Received frozen This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano, CA. This test should not be used for diagnosis without confirmation by other medically established means.

1996 - 2019 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database